Board Committees

The Audit and Finance Committee

View Commitee Charter

Members:
Louis W. Sullivan, M.D., Fred Holubow , Ross J. Mangano

The Committee assists the Board in fulfilling its responsibility for oversight of the quality and integrity of BioSante's financial statements, the quarterly reviews and the annual independent audit of BioSante's financial statements, BioSante's accounting, auditing and financial reporting practices, systems of internal control over financial reporting, disclosure controls and procedures, compliance with legal and regulatory requirements and ethical standards adopted by BioSante.

The Nominating and Corporate Governance Committee

View Commitee Charter

Members:
Stephen A. Sherwin, M.D, Louis W. Sullivan, M.D., Fred Holubow , Ross J. Mangano

The primary purpose of the Committee is to:

  • identify individuals qualified to become Board members;
  • recommend director nominees for each annual meeting of BioSante's stockholders and director nominees to fill any vacancies that may occur between meetings of stockholders;
  • be aware of the best practices in corporate governance and develop and recommend to the Board a set of corporate governance standards to govern the Board, its committees, the company and its employees in the conduct of the business and affairs of the company; and
  • develop and oversee the annual Board and Board Committee evaluation process.

The Compensation Committee

View Commitee Charter

Members:
Louis W. Sullivan, M.D., Ross J. Mangano, Edward C. Rosenow, III, M.D., Stephen A. Sherwin, M.D.

The primary purpose of the Committee is to:

  • discharge the responsibilities of the Board relating to compensation of the CEO and other executive officers;
  • administer BioSante's equity compensation plans;
  • review, assess and approve overall company strategies for attracting, developing, retaining and motivating management and employees; and
  • prepare any report that may be required by applicable law, including without limitation the Committee report on executive compensation for inclusion in BioSante's proxy statement relating to its annual meeting of stockholders, if required.